Get the Daily Brief
Latest Biotech News
Autoantibodies Influence Cancer Immunotherapy Response, Reveals Yale Study
A landmark study by Yale and Fred Hutchinson Cancer Center found that naturally occurring autoantibodies can strongly affect patient responses to checkpoint immunotherapy. Certain autoantibodies...
Sanofi’s $1.15 Billion Bet on Non-mRNA Respiratory Vaccines
Sanofi announced a $1.15 billion upfront acquisition of Vicebio, a London-based biotech developing combination vaccines targeting respiratory syncytial virus (RSV) and human metapneumovirus...
Sarepta Halts Duchenne Therapy Shipments Amid FDA Safety Concerns
Sarepta Therapeutics has reversed its prior stance and agreed to voluntarily pause shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD), following FDA requests tied to...
Thermo Fisher Rises on Q2 Beat and Raised 2025 Outlook
Thermo Fisher Scientific reported Q2 2025 revenue of $10.86 billion, beating analyst estimates, driven by a 6% rise in life sciences solutions. Adjusted earnings per share were $5.36, surpassing...
Abivax’s Obefazimod Shows Promise in Phase 3 Ulcerative Colitis Trials
French biotech Abivax announced positive Phase 3 results for obefazimod, an oral miRNA-124 enhancer for moderate-to-severe ulcerative colitis, showing a 16.4% placebo-adjusted clinical remission...
Dispatch Bio Launches with $216 Million for Universal Solid Tumor Immunotherapy
Dispatch Bio debuted as a new biotech utilizing a viral vector platform named Flare to tag solid tumor cells with a universal antigen, promoting immune clearance without harming healthy tissue....
Long-Read Sequencing Enhances Human Genome Structural Variant Detection
Two international research groups employed Oxford Nanopore long-read sequencing to analyze more than 1,000 genomes from the 1000 Genomes Project, detecting novel structural variants (SVs)...
Genetic CRISPR Edit Blocks Malaria Transmission in Mosquitoes
A research team from UCSD and Johns Hopkins engineered Anopheles stephensi mosquitoes using CRISPR-Cas9 to introduce a naturally occurring FREP1 gene variant that prevents Plasmodium parasite...
AstraZeneca Pledges $50 Billion US Investment Amid Tariff Concerns
AstraZeneca has committed $50 billion over the next five years to manufacturing and R&D projects across the United States, including a new drug factory in Virginia, its largest to date. This...
Replimune Cancer Therapy Faces FDA Setback, Shares Plummet
Replimune Group’s oncolytic virus therapy RP1, intended for advanced melanoma treatment, received a complete response letter from the FDA citing inadequate trial design and heterogeneity of...
Sarepta pauses Duchenne therapy shipments amid FDA safety dispute
Sarepta Therapeutics has voluntarily and temporarily halted shipments of its Duchenne muscular dystrophy gene therapy Elevidys in the US following safety concerns linked to patient deaths and...
Sanofi acquires Vicebio to expand respiratory vaccine portfolio
Sanofi has agreed to acquire London-based biotech Vicebio in a deal valued at $1.15 billion upfront with potential milestone payments of $450 million, aiming to broaden its respiratory vaccine...
Replimune’s oncolytic virus melanoma therapy rejected by FDA
The FDA issued a complete response letter rejecting Replimune Group’s Biologics License Application for RP1, an oncolytic virus therapy combined with nivolumab for advanced melanoma. The agency...
Abivax ulcerative colitis drug shows strong Phase 3 results amid funding pressures
French biotech Abivax’s oral drug obefazimod demonstrated statistically significant clinical remission rates in twin Phase 3 trials for moderate to severe ulcerative colitis, surpassing previous...
Automation and AI-driven advances in biomanufacturing and mRNA production
Emerging innovations in biomanufacturing are leveraging automation, AI, and advanced modeling to streamline processes and reduce costs. Notably, new mathematical models for in vitro transcription...
AstraZeneca commits $50 billion to US manufacturing and R&D expansion
AstraZeneca announced a $50 billion investment plan to expand its U.S. manufacturing and research infrastructure through 2030, including the largest facility it has ever built in Virginia focused...
Cancer immunotherapy innovations and biotech fundraising
The cancer immunotherapy sector sees emerging approaches and substantial funding rounds aiming to tackle solid tumors. Dispatch Bio, a startup backed by $216 million from investors including the...
Biotech industry earnings and market outlook for CDMOs and diagnostics
Contract development and manufacturing organizations (CDMOs) including Lonza, Thermo Fisher, and Samsung Biologics reported earnings exceeding expectations despite client funding challenges and...
Breakthrough cancer and neurodegenerative research advances
Novel research highlights promising therapeutic strategies across oncology and neurology. Identification of autoantibodies influencing immunotherapy response offers a route to improved cancer...
Genomic and bioinformatics innovations enhance precision medicine
Advances in human genome sequencing reveal complex gene duplications linked to brain function and evolutionary traits. Bioinformatics collaborations, such as between TileDB and Databricks,...